ICU Webinar

Please click here to access the recordings (content available for free for EACTAIC members)

ORGANIZED BY THE EACTA EDUCATIONAL COMMITTEE IN COLLABORATION WITH THE INTENSIVE CARE UNIT COMMITTEE
THE CAN WE AVOID ECMO IN THE MANAGEMENT OF POST CARDIOTOMY SHOCK?, 04/11/2019–04/11/2019 HAS BEEN ACCREDITED BY THE EUROPEAN ACCREDITATION COUNCIL FOR CONTINUING MEDICAL EDUCATION (EACCME®) WITH 1 EUROPEAN CME CREDITS (ECMEC®S). EACH MEDICAL SPECIALIST SHOULD CLAIM ONLY THOSE HOURS OF CREDIT THAT HE/SHE ACTUALLY SPENT IN THE EDUCATIONAL ACTIVITY.

A CERTIFICATE OF ATTENDANCE WILL BE ISSUED AFTER THE COURSE AND SENT BY E-MAIL

TARGET AUDIENCE:

ANAESTHESIOLOGY, INTENSIVE CARE, PERFUSION, CARDIAC SURGERY, CARDIAC ANAESTHESIA, VASCULAR ANAESTHESIA, NURSES, MEDICAL STUDENTS AND INTERNS

CHAIR OF THE WEBINAR:

Dr. Philippe Gaudard
France, Chair of EACTA ICU Subspecialty Committee.

SCIENTIFIC MODERATORS:
Dr. Peter Rosseel
Belgium, EACTA ICU Committee.
Dr. Daniela Pasero
Italy, EACTA ICU and VAD and Transplant Committees.
Prof. Alexandre Ouattara
France, Chair of CAPSO congress.
Take-Home Message
  • VA-ECMO for refractory PCCS needs to be started early when inotropes don’t work and needs to be customized to patient and surgical situation, including a combination with IABP
  • LV unloading is mandatory and minimal pulmonary flow needs to be preserved as much as possible
  • Anticipation or prevention is a key point for the use of IABP and probably Levosimendan in selected cases
  • Selective LV support or combined VAD are promising options
  • TEE is absolutely essential for the indication, the setting up, the follow up and the weaning of MCS


Share this event
Event Details
10
Days
50
Hours
10
Min
00
Sec
Start Date
November 04, 2019 5:00 pm
End Date
November 04, 2019 7:00 pm
Status
Expired
Topic Speaker / Moderator
Welcome & Introduction Philippe Gaudard (France), Peter Rosseel (Belgium)
The use of ECMO for post-cardiotomy cardiogenic shock: New merits Moderator: Daniela Pasero (Italy)
Speaker: Antonio Rubino (United Kingdom)
The use of IABP or inotropes for post-cardiotomy cardiogenic shock Moderator: Peter Rosseel (Belgium)
Speaker: Isabelle Michaux (France)
The use of temporary VAD for post-cardiotomy cardiogenic shock Moderator: Daniela Pasero (Italy)
Speaker: Alexandre Ouattara (France)
Routine use of TEE to guide mechanical circulatory support for cardiogenic shock Moderator: Alexandre Ouattara (France)
Speaker: Priya Menon (Germany)
Lessons from intensive care of patients with post-cardiotomy cardiogenic shock Philippe Gaudard (France)
Take Home Message Peter Rosseel (Belgium)
Conclusions Philippe Gaudard (France), Fabio Guarracino — EACTA President (Italy)
sponsors
sponsors

As for any IABP insertion, the risk of occlusion of the left subclavian/left carotid artery exists if the balloon is inserted too far away towards the aortic arch. To avoid this malposition, we should guide the insertion and positioning of the balloon either by RX fluoroscopy, either by TEE (see lecture from Dr P Menon during the webinar), whether or not there is an inserted VA-ECMO. If the VA-ECMO is placed centrally (using the CPB-cannulas) and if the IABP is placed correctly (cf supra), the risk of compromising the upper circulation seems to me quite low. If the ECMO is placed peripherally, based on the available literature, we know that: -Yang et al. J Translational Medicine 2014, 12: 106. Postcardiotomy shock patients. If the heart is producing a pulsatile pressure gradient > 10mmHg, the addition of IABP to peripheral VA ECMO will significantly increase the cerebral blood flow compared to VA-ECMO alone. If the heart is not generating a pulsatile pressure > 10mmHg, the cerebral blood flow will be higher in the group receiving just the VA-ECMO. -Chen et al. Ann Intensive Care 2019; 9:16. Postcardiotomy shock patients, retrospective study. In the group receiving IABP + VA-ECMO, there were less CRRT, less neurological complications, but more thrombosis complications. In this study, the association of IABP + VA-ECMO was an independent protective factor for in-hospital mortality.

I do not have any experience with the use of intratracheal milrinone. The group of A.Denault (Montreal) published about this use in case of acute RV dysfunction (JCVA 2017;31:489) and according to them, it is very powerful and easy to use. However, it is an emergent action helping to avoid RV failure during or just after weaning of CPB. It should be followed by the use of pulmonary vasodilator agents, preferably inhaled to avoid systemic vasoplegia, like inhaled NO or inhaled milrinone. Some colleagues told me that they already tested it in post-cardiotomy acute RV dysfunction, and confirmed that it was very efficient.

Yes, of course. The use of cathecholergic inotropes (Dobutamine, milrinone, epinephrine) is exhausting the ATP reserves of the cardiac muscle, which is the fuel of the myocardium. GIK, through the Krebs cycle, is restoring the ATP reserves. On a theoretical point of view, the association of levosimendan with GIK could be less useful, as levosimendan is supposed to avoid ATP consumption.

Based on the available literature, I may not recommend it as standard care, as there are no multicenter RCT confirming its usefulness in term of benefit on the survival rate. However, the side’s effects that we can induce with GIK are hypo-or hyperglycaemia/ hypo-or hyperkalemia. Glycaemia and K are parameters that are regularly checked by experienced teams during and after cardiac surgery and we are familiar with those corrections. Therefore, I do not consider those side’s effects as an issue. On a clinical point of view and to be pragmatic, I would suggest that every patient operated with CPB and known to have reduced LV EF with signs of elevated end-diastolic pressures, every patient operated in emergency, every patient operated because of acute myocardial ischemia, every patient for whom a prolonged CPB time is expected, may benefit from GIK. The main problem is that it exists as many GIK protocol as published studies.

First of all, we should keep in mind that those data, published by the Danish group, are retrospective data. In this retrospective study, those patients who received milrinone were older, with lower preoperative ejection fraction, higher EuroSCORE, longer time on cardiopulmonary bypass, and having more complex surgery; in other words they were probably more “sick”. Some hypotheses were addressed by this group to try to explain what they observed. 1) Milrinone is a more powerful vasodilator agent than dobutamine, and significant hypotension after cardiac surgery can induce hypoperfusion of coronary, renal and mesenteric arteries, which can be deleterious. 2) Milrinone in nonsurgical acute exacerbation of chronic heart failure (OPTIME-CHF study, J Am Coll Cardiol. 2003;41:997–1003) was shown to be harmful in patients with ischemic heart failure with LVEF < 40%.

There are, in the literature, as many GIK protocol as published data. This explains maybe why it is so difficult to find strong conclusive data in the literature about GIK. The historical formula was: a maximal glucose disposal rate of 400 mg/M2/min with an insulin infusion rate at 1,200 mU/ M2/min and KCI supplement rate at 0.08 mEq/M2/min. The formula proposed by the group of Geneva is 50ml G40% + Actrapid 20UI + 10 mEq KCl over 60min at the time of induction of anaesthesia. When I use it in the ICU after difficult cardiac surgery, I give 500ml G50% in 24h + insulin started at the infusion rate of 0.1U/Kg; the nurses are controlling every 30min glycaemia and K to adapt the infusion rate of insulin and K. Generally, a steady state is reached after +/- 2h. In the toxicologic literature (B-Blocker or Ca channel Blocker intoxication), you can find very high regime of insulin bolus, like 1 U/kg insulin bolus followed by a 1-10 U/kg/h continuous infusion (Clin Toxicol (Phila). 2011 Apr;49(4):277-83).
  • The speakers and attendees will be remote from each other.
  • The speakers, attendees, and moderator will use their own high-speed internet access, HD webcam, personal computer and HD microphone and headset. Any webcam that is recognized by your computer can be used in the system. We recommend higher quality webcams with 2+ Megapixels quality.
  • A dedicated, wired internet connection of at least 5 Mbps download/upload speed is required to present content using The Webinato (USA), the technical solution for the webinar. Click here to check your connection
  • The IT technician from Webinato will run and interact by connecting speakers, moderators, and attendees together, mute non-talking persons, and collect and pass questions to the scientific moderators.
  • Chat and Q & A: Interactive live webinar where the speakers will address the received questions from the attendees within the allocated time limits. The questions will be sent by delegates to the Chat box 1 on the lower-left corner, used for sending questions and for IT support from Webinato to publish announcements. That chat box can be read by all delegates and presenters.
  • If you need support, please don't hesitate to check the Support Website